The burgeoning landscape of treatment for obesity and type 2 glucose intolerance is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 https://kianaxenh114636.mdkblog.com/44945139/retatrutide-vs-tirzepatide-a-comparative-analysis